Tempest Therapeutics’ (TPST) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Tempest Therapeutics (NASDAQ:TPST) in a report issued on Wednesday,Benzinga reports. HC Wainwright currently has a $47.00 target price on the stock. HC Wainwright also issued estimates for Tempest Therapeutics’ Q4 2024 earnings at ($0.19) EPS, FY2024 earnings at ($1.27) EPS, FY2025 earnings at ($0.87) EPS, FY2026 earnings at ($1.07) EPS, FY2027 earnings at ($0.89) EPS and FY2028 earnings at ($1.04) EPS.

Tempest Therapeutics Stock Down 8.3 %

Shares of TPST stock opened at $0.89 on Wednesday. The stock has a 50-day simple moving average of $1.20 and a 200 day simple moving average of $1.95. The stock has a market capitalization of $22.43 million, a P/E ratio of -0.58 and a beta of -1.78. Tempest Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $6.00.

Institutional Trading of Tempest Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new position in Tempest Therapeutics in the third quarter worth approximately $34,000. Empower Advisory Group LLC bought a new stake in shares of Tempest Therapeutics during the 3rd quarter worth $49,000. Dimensional Fund Advisors LP acquired a new position in shares of Tempest Therapeutics in the 2nd quarter worth $55,000. Fullcircle Wealth LLC acquired a new stake in shares of Tempest Therapeutics during the third quarter worth $87,000. Finally, Virtu Financial LLC lifted its holdings in shares of Tempest Therapeutics by 69.2% during the first quarter. Virtu Financial LLC now owns 28,574 shares of the company’s stock valued at $112,000 after purchasing an additional 11,689 shares during the last quarter. 22.52% of the stock is owned by institutional investors and hedge funds.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.